New drug YOLT-202 tested in early trial for rare lung and liver disease
NCT ID NCT07193615
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a single dose of a new drug called YOLT-202 in 18 adults with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal is to see if the drug is safe and to find the best dose. Participants will receive one intravenous infusion and be monitored for side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YOLT-202 (a single-dose intravenous drug)
What this could lead to
If it works, this could point toward a new treatment option for people with Alpha-1 antitrypsin deficiency, a genetic lung and liver condition.
What could go wrong
This is a very early, small study with only 18 participants. It is designed mainly to check safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ren Ji Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, China